Clinical activity of ASP8273 in Asian patients with non‐small‐cell lung cancer with EGFR activating and T790M mutations

Epidermal growth factor receptor (EGFR)‐activating mutations confer sensitivity to tyrosine kinase inhibitor (TKI) treatment for non‐small‐cell lung cancer (NSCLC). ASP8273 is a highly specific, irreversible, once‐daily, oral, EGFR TKI that inhibits both activating and resistance mutations. This ASP...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cancer Sci
Главные авторы: Murakami, Haruyasu, Nokihara, Hiroshi, Hayashi, Hidetoshi, Seto, Takashi, Park, Keunchil, Azuma, Koichi, Tsai, Chun‐Ming, Yang, James Chih‐Hsin, Nishio, Makoto, Kim, Sang‐We, Kiura, Katsuyuki, Inoue, Akira, Takeda, Koji, Kang, Jin‐Hyoung, Nakagawa, Tomoki, Takeda, Kentaro, Akazawa, Rio, Kaneko, Yuichiro, Shimazaki, Masashi, Morita, Satoshi, Fukuoka, Masahiro, Nakagawa, Kazuhiko
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley and Sons Inc. 2018
Предметы:
Original Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6125469/
https://ncbi.nlm.nih.gov/pubmed/29972716
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13724
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы